Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR2010020001429343
PACTR2010020001429343
Other
未知

EVALUATION OF THE SAFETY AND EFFICACY OF MEFLOQUINE AS INTERMITTENT PREVENTIVE TREATMENT FOR MALARIA IN PREGNANCY

FCRB0 sites0 target enrollmentMay 27, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
FCRB
Status
Other
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 27, 2009
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
FCRB

Eligibility Criteria

Inclusion Criteria

  • •Permanent resident in the area
  • •Gestational age at the first antenatal visit \< 28 weeks
  • •Signed informed consent
  • •Agreement to deliver in the study site's maternity wards

Exclusion Criteria

  • •Residence outside the study area or planning to move out in the following 18 months from enrollment
  • •Gestational age at the first antenatal visit \> 28 weeks of pregnancy
  • •Known history of allergy to sulfa drugs or mefloquine
  • •Known history of severe renal, hepatic, psychiatric or neurological disease
  • •MQ or halofantrine treatment in the preceding 4 weeks
  • •HIV infection
  • •Participating in other studies

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
EVALUATION OF THE SAFETY AND EFFICACY OF MEFLOQUINE AS INTERMITTENT PREVENTIVE TREATMENT FOR MALARIA IN PREGNANCY IN HIV+ PATIENTSHIV/AIDSMalariaPregnancy and Childbirth
PACTR2010020001813440FCRB
Completed
Not Applicable
The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy
JPRN-UMIN000022151Department of Neurology, Shimane University Hospital5
Active, not recruiting
Phase 1
Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation. - UK ELiTERenal TransplantationMedDRA version: 7.1Level: PTClassification code 10038533
EUCTR2004-005055-33-GBBarts and the London NHS Trust
Not yet recruiting
Phase 4
Evaluate the efficacy and safety of Artesunate-mefloquine (ASMQ) and low dose primaquine to treat uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Champasack province, Lao PDRMalaria
ACTRN12618001349235Ministry of Health120
Not yet recruiting
Not Applicable
Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis
JPRN-UMIN000003897Department of Infectious Diseases and Infection Control, Jikei University School of Medicine20